Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery

Cannot have received: TNF-α inhibitor

Prior use of TNF-α inhibitor

Cannot have received: CD137 agonist

Prior treatment with CD137 agonists

Cannot have received: immune checkpoint blockade therapy (anti-CTLA-4, anti-PD-1, anti-PD-L1)

Prior treatment with ... immune checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies

Cannot have received: systemic immunosuppressive medication (corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide)

Exception: acute, low-dose or one-time pulse dose; mineralocorticoids; corticosteroids for COPD/asthma; low-dose corticosteroids for orthostatic hypotension or adrenal insufficiency; topical steroids

Treatment with systemic immunosuppressive medication (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide) within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during study treatment

Cannot have received: systemic immunostimulatory agent (interferon, interleukin 2)

Treatment with systemic immunostimulatory agents (including, but not limited to, interferon and interleukin 2 [IL-2]) within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to initiation of study treatment

Cannot have received: investigational therapy

Treatment with investigational therapy within 28 days prior to initiation of study treatment

Cannot have received: therapeutic oral or IV antibiotics

Exception: prophylactic antibiotics

Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment

Cannot have received: allogeneic stem cell or solid organ transplantation

Prior allogeneic stem cell or solid organ transplantation